« Hal C. Scherz, M.D. | Main | Make Research a Centerpiece in Reform »

02/23/2010

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Throughout the health care reform debate much has been made of the USA expending approximately 16% of our gross domestic product (GDP) on health care and how this is a significantly greater percentage compared to other countries.

The fact is that a nation’s expenditure for health care can be viewed as a purchase or as an investment. In most countries around the world GDP health expenditure is for purchase of medical services and products like surgical or diagnostic procedures, drugs and medical devices. In stark contrast, the United States has directed its health expenditure not only for purchase of medical care, but also as an investment in research and development of state of the art medical care. Therefore, it should come as no surprise that most of the progress in biomedical research and medical breakthroughs have occurred within the United States.

This investment has been a blessing not only for Americans but for people around the world in need of state-of the-art care for cancer or a transplant or any one of a host of miraculous-like interventions. The problem is that when one combines the cost of purchase and the cost of investment the price tag is increasingly more expensive.

Congress and the Administration must address the future of health care for Americans with careful consideration of both the price of purchase and the cost of investment. The price of purchase can be reduced without sacrifice of quality by a rational and effective approach to eliminating cost drivers. The cost of investment, however, can only be considered in the context of the return on investment.

The investments we have made are already paying dramatic dividends in lives saved and the best is yet to come. For people threatened by Alzheimer’s, dementia ,diabetes, AIDS, metastatic cancer, pandemic influenza, paralysis and a host of other acute and chronic diseases, health reform must assure them that this nation’s investment in biomedical research and development will continue.

Show your support for research and development on the CHT poll (www.healthtransformation.net).

Why can't we start with the government programs like Medicare and Medicaid reimbursing providers at a rate that is true to the cost of the service? This will bring down the price of services for customers in the private market that are currently subsidizing government customers through higher prices. This will increase the programs' budgets, but the private market could get back to reasonable rates and have relief. Once we have a true cost of the government programs, then we can cut and/or adjust those.

If you want healthcare for all then have all doctors, hospitals and heathcare facilities donate two days a week to those who don't have health insurance and give tax incentives.

The comments to this entry are closed.

Personalized Health Expert Panel

  • Lance Armstrong, Founder and Chairman of LIVESTRONG

    Raymond DuBois, MD, PhD, Provost and Executive Vice President, The University of Texas MD Anderson Cancer Center

    Lloyd K. Everson, MD, Vice Chairman of the Board of Directors of US Oncology, Inc.

    Congressman Phil Gingrey, MD, (GA-11) represents the 11th District of Georgia

    Robert Ingram, General Partner, Hatteras Venture Partners

    Ellen V. Sigal, PhD, Chair & Founder of Friends of Cancer Research

    Mary Woolley, President and CEO, Research!America

Health Information Technology Expert Panel

  • Charlie Jarvis, Vice President, Health Care Services and Government Relations, NextGen Healthcare Information Systems

    Chad A. Eckes, Chief Information Officer, Cancer Treatment Centers of America

    Sarah T. Corley, M.D., Chief Medical Officer, NextGen Healthcare Information Systems

    Jac Davies, Director of Northwest Telehealth, Inland Northwest Health Services

    Senator Tom Daschle, Former Senate Majority Leader

    Kate Berry, Senior Vice President of Market Development, Surescripts

    Harris Frankel, M.D., President, Nebraska Health Information Initiative; President, Metro Omaha Medical Society

    Justin Barnes, Chairman, Electronic Health Record Association; Vice President, Greenway Medical Technologies

    Peter Neupert, Corporate Vice President, Microsoft

Health Justice Expert Panel

  • Newt Gingrich, Founder, Center for Health Transformation

    Sen. Tom Price, MD

    Hal Scherz, MD, President of Docs 4 Patient Care

    John Gill, MD, Lead advocate for Texas Civil Justice Reform Movement

    Jim Morrow, MD, Medical Director, Allscripts

    Jeff Segal, MD, Founder & CEO, Medical Justice Services

    Philip Howard, JD, Founder, The Common Good

    Andy von Eschenbach, MD, former Commissioner of the FDA

    Ga. Sen. Judson Hill

    David Cook, JD, Executive Director, Medical Association of Georgia

Fraud Expert Panel

  • Sen. Tom Coburn, M.D.

    Sen. George LeMieux

    Rep. Michael Burgess, M.D.

    Rep. Dave Reichert

    Scott Serota, President and CEO, BCBSA

    Tom McGraw, Senior Vice President, Ingenix

    Merrit Quarum, M.D.,CEO, Qmedtrix

    Barry Johnson, D.D.S., President and CEO, HealthCare Insight

    Ga. Sen. Judson Hill

    Craig Smith, Partner, Hogan & Hartson

Health Care Cost Expert Panel

  • Newt Gingrich, Founder, Center for Health Transformation

    Rep. Michael Burgess, MD


    Ron Bachman, Senior Fellow, Center for Health Transformation

    James Gelfand, Senior Manager of Health Policy, US Chamber of Commerce

    Scott Serota CEO, Blue Cross Blue Shield Association

    Ryan Mahoney, Director of Public Policy, GA Chamber of Commerce

Individual Health Expert Panel

  • Lynette Bisconti

    Steve Bonner

    Karen Ignagni

    William W. McGuire, MD

    Dwight Mankin

    Amy Protexter

    Wayne A. Sensor

    Congressman John Shadegg

    Ron Wince

President Proposal Expert Panel

  • Newt Gingrich, Founder, Center for Health Transformatin

    John Goodman, President and CEO, National Center for Policy Analysis

    Ron Wince, President anad CEO, Guidon Performance Soutions

    Karen Ignagni, President and CEO, AHIP

    Sreedhar Potarazu, VP and CEO, Vital Spring Technologies

    Tevi Troy, former Deputy Secretary HHS